GEM Premier 5000; Part No. 00055415005.
Publicado el 18 de marzo de 2026 · Inicio del retiro: 20 de enero de 2026
Resumen
FDA registra el retiro Z-1533-2026 de dispositivos médicos de Clase II, publicado el 18 de marzo de 2026 e iniciado el 20 de enero de 2026. Empresa responsable: Instrumentation Laboratory; Estado: En curso; Cantidad reportada: 8 units; Lote: Part number: 00055415005; UDI: 08426950807667; Lots No. 251125S, 251201AJ, 251212O, 251218V, 251229X. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.
Qué hacer
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Instrumentation Laboratory
- Distribuidor
- Worldwide distribution - US Nationwide and the countries of Argentina, Austria, Australia, Belgium, Bulgaria, Brazil, Belarus, Switzerland, Canada, Chile, China, Colombia, Czech Republic, Germany, Denmark, Dominican Republic, Ecuador, Estonia, Spain, Finland, France, United Kingdom, Georgia, Greece, Guatemala, Hong Kong, Croatia, Hungary, Indonesia, Ireland, Israel, India, Italy, Jordan, Japan, South Korea, Kazakhstan, Lebanon, Lithuania, Luxembourg, Latvia, Macau, Mexico, Malaysia, Netherlands, New Zealand, Oman, Panama, Peru, Philippines, Poland, Portugal, Qatar, Romania, Serbia, Saudi Arabia, Sweden, Singapore, Slovenia, San Marino, South Africa, Thailand, Tunisia, Turkey, Uruguay, Uzbekistan & Vietnam.
- Lote
- Part number: 00055415005; UDI: 08426950807667; Lots No. 251125S, 251201AJ, 251212O, 251218V, 251229X.
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAHemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009802028. in vitro diagnostic (OUS only)21 de octubre de 2026
- FDAHemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009800127. in vitro diagnostic21 de octubre de 2026
- FDAGEM Premier 7000 with iQM3 Part Numbers: 00077407508 00077407510 00077415004 00077415008 0007741501012 de agosto de 2026
- FDAGEM Premier 5000 PAK Part Numbers: 00055360010 00055360011 00055407504 00055415010 00055430010 0005543001112 de agosto de 2026
- FDAGEM Premier 5000 PAK, Part No. 00055360004.18 de marzo de 2026
- FDAOwner's Booklets and Instructions for Use that are used with the following blood glucose measurement devices.18 de marzo de 2026
Preguntas sobre este retiro
¿GEM Premier 5000; Part No. 00055415005. fue retirado del mercado?
Sí. FDA publicó el retiro Z-1533-2026 el 18 de marzo de 2026. Peligro reportado: Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit